Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676544 · ClinicalTrials.gov registry record · Phase 1
Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)
A Phase 1 study, sponsored by Rhode Island Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02676544 is a Phase 1 study that was terminated before completion, run by Rhode Island Hospital. The registered enrollment target is 9 participants.
The verdict
NCT02676544, a Phase 1 study, was terminated before completion, sponsored by Rhode Island Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a prospective, open label single center feasibility study to demonstrate basic safety and effectiveness of prostate artery embolization for the treatment of symptomatic benign prostatic Hyperplasia (BPH) in a small series of patients with large (≥90 grams) glands.
Interventions
- DEVICE Embosphere microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-12 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02676544
The ClinicalTrials.gov registry entry for NCT02676544 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhode Island Hospital, which has 130 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Embosphere microspheres is the first listed.
NCT02676544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02676544 about?
NCT02676544 is a clinical study titled "Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)". This is a prospective, open label single center feasibility study to demonstrate basic safety and effectiveness of prostate artery embolization for the treatment of symptomatic benign prostatic Hyperplasia (BPH) in a small series of patients with large (≥90 grams) glands.
What is the current status of trial NCT02676544?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-12. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT02676544?
The interventions under investigation include: Embosphere microspheres (DEVICE).
Who is sponsoring clinical trial NCT02676544?
This trial is sponsored by Rhode Island Hospital, which has 130 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.